Literature DB >> 19902128

Double role of Fas ligand in the apoptosis of intervertebral disc cells in vitro.

Dunfu Han1, Yue Ding, Shang-Li Liu, Gang Wang, In-Cheong Si, Xinguang Wang, Liyang Cui, Dongshang Huang.   

Abstract

Fas ligand (FasL) may play an important role in maintaining the immune privilege of intervertebral disc (IVD). Besides, it is closely related to the apoptosis of degenerative disc cells. Nowadays, lots of reports have described about the paradoxical effects of FasL, although the effect of FasL on IVD cells is still under debate. In this study, we tried to investigate the effects of FasL on Fas expression and on the apoptosis of nucleus pulposus (NP) cells in Sprague-Dawley rats. The results showed that the expression of Fas in NP cells was significantly increased by the recombinant FasL. Meanwhile, the apoptosis of NP cells increased markedly in a FasL dose-dependent manner. Interestingly, RNA interference results indicated that the increase of Fas expression and the NP cell apoptosis described previously were inhibited by Fas siRNA, suggesting that RNA interference might be one of novel strategies to prevent IVD cells from apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19902128     DOI: 10.1093/abbs/gmp087

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  9 in total

1.  Reactive oxygen species-mediated mitochondrial dysfunction plays a critical role in high glucose-induced nucleus pulposus cell injury.

Authors:  Lianjun Yang; Lixin Zhu; Weiren Dong; Yanlin Cao; Lijun Lin; Zijie Rong; Zanjie Zhang; Guofeng Wu
Journal:  Int Orthop       Date:  2013-10-12       Impact factor: 3.075

2.  FasL on human nucleus pulposus cells prevents angiogenesis in the disc by inducing Fas-mediated apoptosis of vascular endothelial cells.

Authors:  Zhen Sun; Zhong-Yuan Wan; Yun-Shan Guo; Hai-Qiang Wang; Zhuo-Jing Luo
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

3.  Expression of soluble Fas and soluble FasL in human nucleus pulposus cells.

Authors:  Zhen Sun; Zhong-Yuan Wan; Zhi-Heng Liu; Yun-Shan Guo; Jun-Bin Yin; Chun-Guang Duan; Yang Gao; Tao Li; Hai-Qiang Wang; Zhuo-Jing Luo
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

4.  RASSF7 expression and its regulatory roles on apoptosis in human intervertebral disc degeneration.

Authors:  Zhi-Heng Liu; Jun-Li Huo; Zhi-Gang Wu; Zhen Sun; Feng Bai; Dino Samartzis; Benjamin Gantenbein; Shao-Di Fan; Hai-Qiang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

5.  Regenerative and immunogenic characteristics of cultured nucleus pulposus cells from human cervical intervertebral discs.

Authors:  Stefan Stich; Meaghan Stolk; Pierre Pascal Girod; Claudius Thomé; Michael Sittinger; Jochen Ringe; Martina Seifert; Aldemar Andres Hegewald
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

6.  Transforming growth factor-β1-regulated Fas/FasL pathway activation suppresses nucleus pulposus cell apoptosis in an inflammatory environment.

Authors:  Jingjing Xie; Bo Li; Bing Yao; Pingchao Zhang; Lixin Wang; Hua Lu; Xuan Song
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

Review 7.  Biologically based therapy for the intervertebral disk: who is the patient?

Authors:  William Mark Erwin
Journal:  Global Spine J       Date:  2013-04-25

8.  Inflammatory Serum Protein Profiling of Patients with Lumbar Radicular Pain One Year after Disc Herniation.

Authors:  Aurora Moen; Anne-Li Lind; Måns Thulin; Masood Kamali-Moghaddam; Cecilie Røe; Johannes Gjerstad; Torsten Gordh
Journal:  Int J Inflam       Date:  2016-05-11

Review 9.  Targeted therapy for intervertebral disc degeneration: inhibiting apoptosis is a promising treatment strategy.

Authors:  Xiao-Bo Zhang; Yi-Cun Hu; Peng Cheng; Hai-Yu Zhou; Xiang-Yi Chen; Ding Wu; Rui-Hao Zhang; De-Chen Yu; Xi-Dan Gao; Jin-Tao Shi; Kai Zhang; Shao-Long Li; Peng-Jie Song; Ke-Ping Wang
Journal:  Int J Med Sci       Date:  2021-05-27       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.